LD50=760 mg/kg (Orally in rats). Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.
A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aclidinium | The risk or severity of adverse effects can be increased when Biperiden is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Biperiden. |
| Mirabegron | The risk or severity of urinary retention can be increased when Biperiden is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Biperiden is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Biperiden. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Biperiden. |
| Tiotropium | The risk or severity of adverse effects can be increased when Biperiden is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Biperiden is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Biperiden is combined with Umeclidinium. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Methylphenidate is combined with Biperiden. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Biperiden. |
| Metoclopramide | The therapeutic efficacy of Biperiden can be decreased when used in combination with Metoclopramide. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Biperiden. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Biperiden is combined with Glycopyrronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Biperiden is combined with Botulinum toxin type A. |
| Glucagon | Biperiden may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Biperiden may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Biperiden is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Biperiden is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Biperiden is combined with Ramosetron. |
| Naltrexone | The risk or severity of adverse effects can be increased when Biperiden is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Biperiden is combined with Bezitramide. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Biperiden is combined with Hydromorphone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Biperiden is combined with Butorphanol. |
| Pentazocine | The risk or severity of adverse effects can be increased when Biperiden is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Biperiden is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Biperiden is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Biperiden is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Biperiden is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Biperiden is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Biperiden is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Biperiden is combined with Diphenoxylate. |
| Dezocine | The risk or severity of adverse effects can be increased when Biperiden is combined with Dezocine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Biperiden is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Biperiden is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Biperiden is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Biperiden is combined with Diamorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Biperiden is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Biperiden is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Biperiden is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Biperiden is combined with Carfentanil. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Biperiden is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Biperiden is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Biperiden is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Biperiden is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Biperiden is combined with Lofentanil. |
| Normethadone | The risk or severity of adverse effects can be increased when Biperiden is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Biperiden is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Biperiden is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Biperiden is combined with Nicomorphine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Biperiden is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Biperiden is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Biperiden is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Biperiden is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Biperiden is combined with Carfentanil, C-11. |
| Codeine | The risk or severity of adverse effects can be increased when Biperiden is combined with Codeine. |
| Methadone | The risk or severity of adverse effects can be increased when Biperiden is combined with Methadone. |
| Meperidine | The risk or severity of adverse effects can be increased when Biperiden is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Biperiden is combined with Oxycodone. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Biperiden is combined with Dextropropoxyphene. |
| Buprenorphine | The risk or severity of adverse effects can be increased when Biperiden is combined with Buprenorphine. |
| Hydrocodone | The risk or severity of adverse effects can be increased when Biperiden is combined with Hydrocodone. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Biperiden is combined with Oxymorphone. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Biperiden is combined with Ethylmorphine. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Biperiden is combined with Dihydrocodeine. |
| Tapentadol | The risk or severity of urinary retention and constipation can be increased when Biperiden is combined with Tapentadol. |
| Opium | The risk or severity of adverse effects can be increased when Biperiden is combined with Opium. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Biperiden is combined with Benzhydrocodone. |
| Morphine | The risk or severity of adverse effects can be increased when Biperiden is combined with Morphine. |
| Naloxegol | The risk or severity of adverse effects can be increased when Biperiden is combined with Naloxegol. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Biperiden. |
| Tropicamide | The risk or severity of adverse effects can be increased when Tropicamide is combined with Biperiden. |
| Amantadine | The risk or severity of adverse effects can be increased when Biperiden is combined with Amantadine. |
| Cyclopentolate | The risk or severity of adverse effects can be increased when Biperiden is combined with Cyclopentolate. |
| Pentolinium | The risk or severity of adverse effects can be increased when Biperiden is combined with Pentolinium. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Biperiden is combined with Trimethaphan. |
| Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione | The risk or severity of adverse effects can be increased when Biperiden is combined with Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione. |
| Agmatine | The risk or severity of adverse effects can be increased when Biperiden is combined with Agmatine. |
| Homatropine | The risk or severity of adverse effects can be increased when Biperiden is combined with Homatropine. |
| Batefenterol | The risk or severity of adverse effects can be increased when Biperiden is combined with Batefenterol. |
| Chlorphenoxamine | The risk or severity of adverse effects can be increased when Biperiden is combined with Chlorphenoxamine. |
| Quinidine | The risk or severity of adverse effects can be increased when Biperiden is combined with Quinidine. |
| Cimetropium | The risk or severity of adverse effects can be increased when Biperiden is combined with Cimetropium. |
| Methyclothiazide | The serum concentration of Methyclothiazide can be increased when it is combined with Biperiden. |
| Chlorthalidone | The serum concentration of Chlorthalidone can be increased when it is combined with Biperiden. |
| Bendroflumethiazide | The serum concentration of Bendroflumethiazide can be increased when it is combined with Biperiden. |
| Metolazone | The serum concentration of Metolazone can be increased when it is combined with Biperiden. |
| Benzthiazide | The serum concentration of Benzthiazide can be increased when it is combined with Biperiden. |
| Hydroflumethiazide | The serum concentration of Hydroflumethiazide can be increased when it is combined with Biperiden. |
| Indapamide | The serum concentration of Indapamide can be increased when it is combined with Biperiden. |
| Chlorothiazide | The serum concentration of Chlorothiazide can be increased when it is combined with Biperiden. |
| Hydrochlorothiazide | The serum concentration of Hydrochlorothiazide can be increased when it is combined with Biperiden. |
| Trichlormethiazide | The serum concentration of Trichlormethiazide can be increased when it is combined with Biperiden. |
| Polythiazide | The serum concentration of Polythiazide can be increased when it is combined with Biperiden. |
| Quinethazone | The serum concentration of Quinethazone can be increased when it is combined with Biperiden. |
| Cyclopenthiazide | The serum concentration of Cyclopenthiazide can be increased when it is combined with Biperiden. |
| Epitizide | The serum concentration of Epitizide can be increased when it is combined with Biperiden. |
| Ziprasidone | The therapeutic efficacy of Biperiden can be decreased when used in combination with Ziprasidone. |
| Olanzapine | The therapeutic efficacy of Biperiden can be decreased when used in combination with Olanzapine. |
| Clozapine | The serum concentration of Clozapine can be increased when it is combined with Biperiden. |